We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Noul Showcases AI-Driven Blood and Cancer Diagnostic Platform

By LabMedica International staff writers
Posted on 15 Nov 2023

Noul Co. More...

, Ltd. (Gyeonggi-do, Korea) is showcasing its AI-driven blood and cancer diagnostic platform, miLab, alongside its new product for automatically staining and analyzing cervical cells, at MEDICA 2023.

Based on its AI-based electro-dynamic blood diagnostic platform miLab, Noul offers various solutions. miLab MAL performs diagnostic processes from staining, and digital imaging to AI analysis with ~5µL of blood from fingertips and diagnoses malaria infection within 15 minutes by analyzing up to 300,000 red blood cells. miLab BCM performs diagnostic processes from staining, and digital imaging to AI analysis with ~5µL of blood obtained through fingertips or from veins. It provides high-definition digital images of white blood cells, red blood cells, and platelets, as well as pre-classification. miLab CER performs diagnostic processes from staining, and digital imaging to AI analysis on cervical cells and analyzes each cell’s characteristics to provide analysis results grouped into stages.

Noul’s new product unveiled at MEDICA 2023, ‘miLab Cartridge CER’ is designed for automatically staining and analyzing cervical cells. It stains cervico-vaginal samples smeared manually or by LBC using the Papanicolaou staining combined with NGSI, a solid-based staining technology developed by Noul. When used with miLab, Noul’s AI-based diagnostic platform, it provides staining, imaging, and cell analysis results that assist user’s decision-making. Through the launch of its new product, the company aims to contribute to the early diagnosis of cervical cancer, the fourth largest cancer in the world for women.

Related Links:
Noul Co., Ltd. 


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Automatic Hematology Analyzer
LABAS F9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.